On June 11, 2018, Zymeworks Inc. (Zymeworks) closed its underwritten public offering of 6,210,000 common shares, including the underwriters’ full exercise of their over-allotment option to purchase 810,000 additional shares, at a price to the public of US$15.75 per common share, for aggregate gross proceeds to the Company of approximately US$97.8 million, before deducting the underwriting discounts and commissions and estimated Offering expenses.
Citigroup Global Markets Canada Inc. and Wells Fargo Securities Canada, Ltd. acted as joint book-running managers for the Offering. Raymond James Ltd. acted as passive bookrunner and Paradigm Capital Inc. acted as co-manager. MTS Securities, LLC served as financial advisor to Zymeworks in the Offering.
Blake, Cassels & Graydon LLP acted as Canadian counsel for Zymeworks, with a team led by Joseph Garcia and included Steven McKoen, Kevin Zimka, Jamie Kariya, Evan Griffith and Daniel Cherniak.
Zymeworks’ US counsel was Skadden, Arps, Slate, Meagher & Flom LLP, with a team consisting of Riccardo Leofanti, Colin Brown, Maia Bessemer, Robert Stevenson, Avia Dunn and Georgian Dimopoulos.
The underwriters were represented in the US by Cooley LLP, with a securities team that included Charlie Kim, Dave Peinsipp, Drew Williamson, Kristin VanderPas, Denny Won and Lindsey Crump; and in Canada by McCarthy Tétrault LLP, with a team that included David Frost, Bosa Kosoric, Claire Sung and Ainslie Hurd.